Authors
Latest:
Cancer Care More Accessible Thanks to Launch of Telehealth and In-Home Infusion programsChevon Rariy, MD, outlines patient eligibility criteria, and the alterations to the nurse patient relationship, as CTCA launches the novel Oncology Clinic at Home Program.
Latest:
Sylvester’s Sexual Health After Cancer Program Expands to Meet Needs of Women with CancerKristin E. Rojas, M.D., FACS, FACOG, assistant professor of surgical oncology in the DeWitt Daughtry Department of Surgery and Sylvester Comprehensive Cancer Center at the University Miami Miller School of Medicine, realized she had struck a chord with women being treated for cancer when she started the Menopause Urogenital Sexual Health and Intimacy Clinic (MUSIC).
Latest:
Recognition of the Advanced Practice Preceptor Role in OncologyA tiered level preceptor recognition program offers a cost-effective organizational intervention designed to acknowledge and incentivize the contributions of advanced practice preceptors.
Latest:
Wheatley and Gopalsami Highlight the Value of Interdisciplinary Collaboration in HSCT CareTia Wheatley, DNP, RN, AOCNS, BMTCN, and Shivani Gopalsami, RN, MSN, ANP-BC, AOCNP, discuss the benefits and challenges of multidisciplinary collaboration in hematopoietic stem cell transplant care.
Latest:
Darolutamide Combination May Delay Disease Progression in Metastatic Hormone-Sensitive Prostate CancerAdding darolutamide to androgen deprivation therapy and docetaxel delayed the progression from metastatic hormone-sensitive prostate cancer to metastatic castration-resistant disease.
Latest:
Overcoming The Burden of Guilt as A NurseJanice Post-White, PhD, RN, FAAN, an oncology nurse and caregiver, discusses how she handled the guilt she felt following her son’s leukemia diagnosis.
Latest:
Mehra Details the Importance of PD-L1 Expression in HNSCC Treatment SelectionRanee Mehra, MD, discusses the link between PD-L1 expression and increased immunotherapy efficacy in head and neck squamous cell carcinoma, and what future treatment options may look like for patients in this space.
Latest:
Advanced Practice Providers Are Uniquely Suited for Survivorship CareAdvanced practice providers are the future of survivorship care because of the tremendous value they offer to the practice and its patients.
Latest:
Unmet Needs and Future Directions in the Management of CIMMartin Dietrich, MD, PhD, and Edgardo Santos, MD, FACP, offer closing remarks on unmet needs and future directions in the management of CIM including other disease states where trilaciclib may offer myeloprotective benefit.
Latest:
Osimertinib Sustains OS Improvement in EGFR-Mutant NSCLCOsimertinib monotherapy and combination treatment had safety profiles consistent with previous data on use of the drug in EGFR-mutated NSCLC.
Latest:
Advancing CML Management Towards an Ideal Patient JourneyThe panel concludes its discussion with insights on challenges and unmet needs in the CML treatment landscape, highlighting ways to better support patients and caregivers.
Latest:
Key Takeaways for Patients With MyelofibrosisPatients with myelofibrosis should reflect on their personal priorities and quality of life goals, understand the range of available JAK inhibitor treatment options, and openly communicate with their doctor to arrive at a shared decision for managing their disease.
Latest:
Colorectal Cancer Screening: Education, Advocacy, and ActionIt is essential to continue to develop and incorporate educational strategies to increase screening for colorectal cancer in our communities.
Latest:
Discrepancies Exist Between Actual Care and Trial-Based Recommendations in MCLDiscrepancies exist between actual patterns of care and recommendations based on clinical trials in adult patients with mantle cell lymphoma.
Latest:
Enfortumab Vedotin and Pembrolizumab Effective in Treating Primary UTUC LesionsEnfortumab vedotin alone and in combination with pembrolizumab showed promise in patients with upper tract urothelial carcinoma, particularly those ineligible for standard chemotherapy.
Latest:
Oncology Drug Crash Course: Tucatinib and Trastuzumab for HER2+ CRCTucatinib was first approved by the FDA for the treatment of patients with HER2-positive advanced unresectable or metastatic breast cancer in combination with trastuzumab and capecitabine on April 17, 2020.
Latest:
Evolving Treatment Strategies in Early HER2+ Breast CancerExperts discuss how, nearly half of patients diagnoses with HER-2 positive metastatic brain cancer do develop brain metastasis. It is thought that larger molecule treatments such as the monoclonal antibodies likely do not cross an intact blood brain barrier which is often why patients develop brain metastases
Latest:
T-Cell Engagers Take Center Stage in Large B-Cell LymphomaBispecific antibodies that engage T cells are an effective treatment modality in relapsed/refractory disease and are an important new treatment for relapsed large B-cell lymphoma.
Latest:
Opinion: Now Is the Time to Optimize Electronic Health Record SystemsBuying one for your practice or enhancing the one you have will help you cut costs and boost your financial stability.
Latest:
Closing Reflection: A Journey of Understanding and ResiliencePanelists discuss how emerging treatments, digital health tools, and enhanced care coordination could streamline disease management and improve quality of life while identifying opportunities to strengthen provider communication and access to resources.
Latest:
Kristin Daly on the Difference Between Somatic and Germline Variants in Precision OncologyKristin M. Daly, MSN, ANP-BC, AOCNP, highlights the difference between somatic and germline variants.
Latest:
Cleveland Clinic Opens New Cancer Center in Abu DhabiThe state-of-the-art facility represents the organization’s vision of global cancer care
Latest:
Oncology Drug Crash Course: Pirtobrutinib (Jaypirca)Sharon Kauffman, PhD, RN, CNE, NPD-BC, OCN, provides an in-depth look at pirtobrutinib in a downloadable reference sheet.
Latest:
Innovative Program Reduces Nurse Turnover and Fosters DevelopmentThe US Oncology Network (The Network) has developed one of the most comprehensive programs in the nation to support the professional development and retention of new oncology nurses.
Latest:
COVID-19 and the Rise of Texting in Health CareThe last thing patients want is to be put on hold or interrupted by calls at work.
Latest:
How Social Media Helps AYA Patients With Cancer Find SupportThe rise of social media platforms has helped foster a community for adolescent and young adult patients with cancer.
Latest:
Informing Patients With Cancer About the Potential Impact of Immunotherapy on PregnancyAn expert explores the complexities of immunotherapy during pregnancy, highlighting risks to the fetus and the crucial role of oncology nurses in patient education and management.
Latest:
Kara Morris and Christine Wylie on Oral Cryotherapy for Chemotherapy-Induced Mucositis in Breast CancerKara Morris, MSN, RN, OCN; and Christine Wylie, MSN, RN, OCN, discuss the benefits of oral cryotherapy for patients receiving dose-dense doxorubicin.
Latest:
Elotuzumab/PVd Combo Elicits Response in Relapsed/Refractory MMElotuzumab plus pomalidomide, bortezomib, and dexamethasone showed tolerability in patients with relapsed or refractory multiple myeloma.
Latest:
Improved PFS Outcomes With Elacestrant Correlate With CDK4/6 Duration in ER+/HER2– Metastatic Breast CancerLonger duration of CDK4/6 inhibitor prior to treatment with elacestrant correlated with progression-free survival (PFS) improvements in patients with estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer vs standard-of-care options.
